| Document |
Document Title |
|
JP2006511525A |
The invention relates to a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by a photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm. The nanopart...
|
|
JP2006508945A |
The present invention relates to methods of preventing and treating aldosterone-mediated diseases such as cardiovascular diseases in women comprising administering a drug agent with combined antimeneralocorticoid and progrestational acti...
|
|
JP2006508962A |
This invention relates to processes for the preparation of novel 7-carboxy substituted steroid compounds of Formula I,
|
|
JP2006507369A |
The present invention provides 5-androsten-3beta-ol steroid intermediates and processes for their preparation.
|
|
JP2006505624A |
The present invention involves intermediates, including a 7alpha-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
|
|
JP3710470B2 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid recept...
|
|
JP2005528371A |
The present invention involves intermediates, including a 7alpha-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
|
|
JP2005213144A |
To provide a new triterpene compound and a derivative thereof useful in the field of foods, medicines, quasi-drugs, cosmetics, etc., and to provide a COX (cyclooxygenase) inhibitor and an LO (lipoxygenase) inhibitor comprising the same.T...
|
|
JP2005523306A |
The present invention involves intermediates, including a 7alpha-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
|
|
JP2004537506A |
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy...
|
|
JP2004534796A |
A process for the preparation of compounds of formula (I) in which R1, R2, R3 and n are defined as indicated in the description, use of said compounds as intermediates for the preparation of estrogen derivatives as well as the intermedia...
|
|
JP2004534042A |
Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding alpha,beta-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the alpha,beta-unsaturated ketone structure...
|
|
JP2004521951A |
A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continu...
|
|
JP2004518611A |
Aldosterone blockers used for the treatment and prevention of inflammation are disclosed
|
|
JP2004511435A |
A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory di...
|
|
JP2004509900A |
The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses i...
|
|
JP2004509900A5 |
|
|
JP2004507495A |
Aldosterone receptor antagonists for the prevention and treatment of cognitive dysfunction are disclosed.
|
|
JP2004505060A |
Combinations of aldosterone blockers an Cyclooxygenase-2 inhibitors useful in the treatment of inflammation are disclosed.
|
|
JP2004501099A |
A pharmaceutical composition is provided for administration to a subject mammal such as a human exhibiting a diurnal cycle of plasma aldosterone concentration, the composition comprising a delayed-release formulation of an aldosterone an...
|
|
JP2004002339A |
To provide a simple and efficient method for purifying 7α-OH-DHEA (7α-hydroxydehydroepiandrosterone) and a part of its derivative in an industrial scale; and to provide the obtained solvated product.A crude reaction product containing ...
|
|
JP3466651B2 |
PURPOSE: To obtain a new steroid which contains a methylene lactone group on 17-th position, which shows various hormonal activities and antihormonal activities and which is useful as a therapeutic drug for prostatic hyperfrophy, virilis...
|
|
JP3466645B2 |
PURPOSE: To obtain the compd. free from by-products at high yield by using specified halohydrin as a starting raw material and bringing this to react under specified conditions. CONSTITUTION: Halohydrin of formula I (X is chlorine or the...
|
|
JP3462515B2 |
PURPOSE: To obtain the subject new compounds that have notable affinity to progesterone receptors, have little affinity to mineral corticoids, and are useful as drugs contg. anti-progestin activity having improved selectivity. CONSTITUTI...
|
|
JP2003531148A |
An efficient method for the synthesis of aminosterol compounds such as squalamine and compound 1436 is described. A method of the invention provides for regioselective sulfonation of a fused ring system. The fused ring system base can be...
|
|
JP2003528137A |
The present invention features methods of inhibiting progestin activity in a cell or in a subject in need of such inhibition, and methods of treating or preventing progestin-dependent conditions in a subject in need of such treatment or ...
|
|
JP3445271B2 |
Compounds of formula (I), wherein R17 and R'17 are such that: either R17 and R'17 together form ketone, hydrazono, oxime or methylene, or R17 is hydroxyl, hydroxymethyl or acyloxy and R'17 is hydrogen, alkyl or optionally substitued alke...
|
|
JP2003522728A |
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
JP3418428B2 |
PURPOSE: To provide the novel steroid compounds whose steroid skeleton is bound at carbon atom 17 to a spiromethylene ring having progestational activity and antiprogenstational activities, and useful as contraceptive medicines. CONSTITU...
|
|
JP3356525B2 |
The invention relates to the compounds (I): R = oxo or beta -OH and A and B represent a free or protected 3-keto- DELTA <4> or DELTA <1,4> residue, their preparation, their application to the preparation of the compounds (A): R3 is a hyd...
|
|
JP3337689B2 |
Compounds of the formula or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from the group consisting of hydrogen and C1-10 alkyl; R2 is selected from the group consisting of hydrogen and C1-10 alkyl; R3 is se...
|
|
JP2002522380A |
Novel methods of treating and/or inhibiting development of prostatic cancer, benign prostatic hyperplasia, prostatitis, acne, seborrhea, hirsutism or androgenic alopecia utilize inhibitors of type 3 3 alpha -hydroxysteroid dehydrogenase ...
|
|
JP3273010B2 |
To obtain a compound useful for treating a disease corresponding to a sex steroid. This sex steroid inhibitor has a molecular structure of formula I (a dotted line is a double bond; R5 and R6 are each H, hydroxyl, etc.; R100 is a divalen...
|
|
JP2002506077A |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17beta-hydroxys...
|
|
JP2002060384A |
To obtain a compound useful for treating breast cancer or other diseases promoted by their exacerbation due to the activation of sex steroid receptor, and to provide a medicament composition containing the above compound.This compound ha...
|
|
JP3231901B2 |
PURPOSE: To obtain the subject compd. having progestational activity and antiesterogenic activity by a new method using a specified compd. as the starting material. CONSTITUTION: First, a compd. expressed by formula I (R1 is a 1-3C alkyl...
|
|
JP2001518896A |
This invention provides estra-5(10),7-dien-3 beta -ol-17-one or a pharmaceutically acceptable salt of its 3-sulfate ester, estra-5(10),7-dien-3 beta -ol-17-one 3-glucuronide or a pharmaceutically acceptable salt thereof, estra-5(10),7-di...
|
|
JP2001509792A |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula Iwherein-A-A- represents the group -CHR4-CHR5- or -CR4=CR5-;R3, R4 and R5 are in...
|
|
JP3181589B2 |
PCT No. PCT/EP91/02493 Sec. 371 Date Oct. 27, 1993 Sec. 102(e) Date Oct. 27, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11277 PCT Pub. Date Jul. 9, 1992Compounds of the general formula I (I) are described, in which x represents an ox...
|
|
JP2001508079A |
PCT No. PCT/EP98/00377 Sec. 371 Date Jul. 14, 1999 Sec. 102(e) Date Jul. 14, 1999 PCT Filed Jan. 13, 1998 PCT Pub. No. WO98/31702 PCT Pub. Date Jul. 23, 1998The present invention relates to certain 16-hydroxy-11-(substituted phenyl)-estr...
|
|
JP3168542B2 |
The invention is directed to the control of cellular autophagy, cellular agglutination and the immobilization of motile cells. Such control is useful in, for example, the treatment of cancer, contraception, termination of pregnancy, remo...
|
|
JP2001072597A |
To provide a novel anti-herpes viral agent. This antiviral agent includes, as an active ingredient, a steroid glycoside that is typified by dioscin represented by the formula and is useful for the therapy of diseases caused by the herpes...
|
|
JP2001503732A |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
JP2000256390A |
To obtain a medicine composition useful for treating diseases related to estrogen and androgen by making the composition include a pharmacologically acceptable diluent, or the like, and a specific sex steroid activity inhibitor. This com...
|
|
JP3065109B2 |
Products of formula (I): in which: R = H, alkyl, alkenyl, alkynyl, haloalkyl or alkylthio, (-> 6c) or arylthio, aryl, acyl (-> 12c) or CN (CH2)m-Rc in which Rc denotes OH, SH or Salk (1 to 6c), cycloalk (3 to 6c), m = 1, 2 or 3, X = O N-...
|
|
JP3058710B2 |
The present invention is directed to a group of compounds which are haloethyl substituted steroidal enzyme inhibitors. These compounds are useful as aromatase, 19-hydroxylase, and aldosterone biosynthesis inhibitors.
|
|
JP3048636B2 |
PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable ...
|
|
JP3048637B2 |
PCT No. PCT/EP91/02495 Sec. 371 Date Feb. 25, 1994 Sec. 102(e) Date Feb. 25, 1994 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11279 PCT Pub. Date Jul. 9, 1992.New D-homo-(16-ene)-11 beta -aryl-4-estrenes of general formula I (I) as well as...
|
|
JP3037507B2 |
PURPOSE: To prepare the new compounds each of which is useful as an intermediate for producing a pregnatrienedione type steroid compound. CONSTITUTION: The derivatives are compounds represented by the formula I (wherein: Hal is Cl or Br;...
|
|
JP2999257B2 |
PCT No. PCT/EP91/01017 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18917 PCT Pub. Date Dec. 12, 1991.The invention includes compounds of the following formula where A and B either A...
|
